Myriad Genetics swings to Q4 profit on license payment
(Reuters) - Myriad Genetics Inc swung to a quarterly net profit, helped by a one-time upfront license payment, and added that it is considering strategic options, including a possible separation of its molecular diagnostic business from pharmaceutical business.
More: continued here